MA42818A - Modulateurs de récepteurs de type toll pour le traitement du vih - Google Patents
Modulateurs de récepteurs de type toll pour le traitement du vihInfo
- Publication number
- MA42818A MA42818A MA042818A MA42818A MA42818A MA 42818 A MA42818 A MA 42818A MA 042818 A MA042818 A MA 042818A MA 42818 A MA42818 A MA 42818A MA 42818 A MA42818 A MA 42818A
- Authority
- MA
- Morocco
- Prior art keywords
- toll
- receptor modulators
- type receptor
- hiv treatment
- hiv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Quinoline Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562218858P | 2015-09-15 | 2015-09-15 | |
US201662382550P | 2016-09-01 | 2016-09-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA42818A true MA42818A (fr) | 2018-07-25 |
Family
ID=56997570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA042818A MA42818A (fr) | 2015-09-15 | 2016-09-13 | Modulateurs de récepteurs de type toll pour le traitement du vih |
Country Status (8)
Country | Link |
---|---|
US (2) | US20180263985A1 (fr) |
EP (1) | EP3349757A1 (fr) |
JP (1) | JP2018527366A (fr) |
AU (1) | AU2016322763A1 (fr) |
CA (1) | CA2997955A1 (fr) |
HK (1) | HK1257270A1 (fr) |
MA (1) | MA42818A (fr) |
WO (1) | WO2017048727A1 (fr) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20211456T1 (hr) | 2014-12-26 | 2021-12-24 | Emory University | Protuvirusni derivati n4-hidroksicitidina |
CU20180011A7 (es) | 2015-03-04 | 2018-06-05 | Gilead Sciences Inc | Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll |
PL3507276T3 (pl) | 2016-09-02 | 2022-02-21 | Gilead Sciences, Inc. | Związki modulatory receptorów toll-podobnych |
WO2018045150A1 (fr) * | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Dérivés de 4,6-diamino-pyrido [3,2-d] pyrimidine en tant que modulateurs du récepteur de type toll |
FR3066761B1 (fr) * | 2017-05-23 | 2020-10-30 | Centre Nat Rech Scient | Nouveaux composes inhibiteurs des canaux ioniques |
CN108069963B (zh) * | 2017-11-17 | 2020-01-14 | 清华大学 | 吡啶并嘧啶衍生物或其盐及其制法、药物组合物和用途 |
JP6804790B1 (ja) | 2017-12-07 | 2020-12-23 | エモリー ユニバーシティー | N4−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 |
US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
CN111094289B (zh) * | 2018-07-03 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
US20200113912A1 (en) | 2018-09-12 | 2020-04-16 | Silverback Therapeutics, Inc. | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates |
TWI751517B (zh) * | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751516B (zh) * | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202115056A (zh) | 2019-06-28 | 2021-04-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
KR20220047277A (ko) * | 2019-07-16 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
KR20220047607A (ko) * | 2019-08-19 | 2022-04-18 | 상하이 지멍 바이오파마 아이엔씨 | 2-아미노피리미딘 화합물 및 이의 약학적 조성물 및 용도 |
AR120096A1 (es) | 2019-09-30 | 2022-02-02 | Gilead Sciences Inc | Vacunas para vhb y métodos de tratamiento de vhb |
WO2021067644A1 (fr) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Polythérapie comprenant des conjugués immunostimulants |
EP3821890A1 (fr) * | 2019-11-18 | 2021-05-19 | Strumberg, Dirk | Compositions pharmaceutiques comprenant un inhibiteur de l'histone désacétylase (hdaci) et un agoniste de récepteur de type toll 7 et/ou 8 (tlr7 et/ou tlr8) et leur utilisation dans le traitement du cancer |
CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
EP4085914A4 (fr) * | 2020-01-02 | 2023-06-21 | Jiangsu Hengrui Medicine Co., Ltd. | Forme cristalline d'un dérivé de pyridopyrimidine et son procédé de préparation |
EP4106819A1 (fr) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Conjugués d'anticorps de nectine-4 et leurs utilisations |
WO2021188959A1 (fr) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Promédicaments de nucléosides de 4'-c-substitué-2-halo-2'-désoxyadénosine et leurs procédés de fabrication et d'utilisation |
WO2022006327A1 (fr) | 2020-07-01 | 2022-01-06 | Silverback Therapeutics, Inc. | Conjugués d'anticorps anti-asgr1 et leurs utilisations |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
CN116437958A (zh) | 2020-11-11 | 2023-07-14 | 吉利德科学公司 | 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法 |
TW202348237A (zh) | 2021-05-13 | 2023-12-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
CA3222439A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composes modulant les diacylglycerol kinases |
WO2022271677A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés de modulation de la diacylglycérol kinase |
AU2022297367A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN118355020A (zh) | 2021-12-03 | 2024-07-16 | 吉利德科学公司 | Hiv病毒感染的治疗性化合物 |
IL312718A (en) | 2021-12-03 | 2024-07-01 | Gilead Sciences Inc | Therapeutic compounds for HIV infection |
US20230212148A1 (en) | 2021-12-03 | 2023-07-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
US20240034724A1 (en) | 2022-07-01 | 2024-02-01 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4724232A (en) | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
CS263952B1 (en) | 1985-04-25 | 1989-05-12 | Holy Antonin | Remedy with antiviral effect |
WO1987001284A1 (fr) | 1985-08-26 | 1987-03-12 | United States Of America, Represented By The Unite | Inhibition du caractere infectieux et de l'effet cytopathique du htlv-iii/lav in vitro par la 2',3'-dideoxyinosine, 2',3'-dideoxyguanosine, ou 2',3'-dideoxyadenosine |
US6492352B1 (en) | 1985-10-31 | 2002-12-10 | Astra Lakemedel Aktiebolag | Method for the control and treatment of acquired immunodeficiency syndrome (AIDS) |
US4978655A (en) | 1986-12-17 | 1990-12-18 | Yale University | Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses |
US5028595A (en) | 1987-09-18 | 1991-07-02 | Hoffmann-La Roche Inc. | Method for preventing AIDS in a subject or treating a subject infected with the AIDS virus |
US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
US5366972A (en) | 1989-04-20 | 1994-11-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection |
US5539122A (en) | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
GB8927913D0 (en) | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
US5563142A (en) | 1989-12-28 | 1996-10-08 | The Upjohn Company | Diaromatic substituted compounds as anti-HIV-1 agents |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
US5519021A (en) | 1992-08-07 | 1996-05-21 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5646180A (en) | 1995-12-05 | 1997-07-08 | Vertex Pharmaceuticals Incorporated | Treatment of the CNS effects of HIV |
US5849911A (en) | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
AU2005285513B2 (en) | 2004-05-25 | 2011-02-24 | Oregon Health And Science University | SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors |
AU2006244497B2 (en) | 2005-05-06 | 2011-09-22 | Providence Health & Services - Oregon | Trimeric OX40L-immunoglobulin fusion protein and methods of use |
WO2006135993A1 (fr) * | 2005-06-24 | 2006-12-28 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines et compositions pharmaceutiques destinees au traitement de l'hepatite c |
TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯 |
WO2008077649A1 (fr) * | 2006-12-26 | 2008-07-03 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines utiles pour traiter des infections virales |
TW200840584A (en) * | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
EA201200631A1 (ru) | 2007-11-16 | 2012-11-30 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
ES2526887T3 (es) | 2007-12-14 | 2015-01-16 | Bristol-Myers Squibb Company | Método para producir moléculas de unión al receptor OX40 humano |
DK2313111T3 (da) | 2008-08-01 | 2013-12-02 | Ventirx Pharmaceuticals Inc | Toll-lignende receptoragonistformuleringer og anvendelse deraf |
SI3260136T1 (sl) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
RU2580320C2 (ru) | 2009-08-18 | 2016-04-10 | Вентиркс Фармасьютикалз, Инк. | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора |
US8691809B2 (en) | 2009-08-18 | 2014-04-08 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
US20110305670A1 (en) | 2010-06-10 | 2011-12-15 | President And Fellows Of Harvard College | Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection |
CN103140474A (zh) | 2010-07-02 | 2013-06-05 | 吉里德科学公司 | 治疗aids的萘-2-基乙酸衍生物 |
CA2802492C (fr) | 2010-07-02 | 2018-10-16 | Gilead Sciences, Inc. | Derives d'acide 2-quinolinyl-acetique en tant que composes antiviraux contre le vih |
EP2611465A4 (fr) | 2010-08-31 | 2014-06-04 | Theraclone Sciences Inc | Anticorps neutralisants anti-virus de l'immunodéficience humaine (vih) |
WO2012045089A2 (fr) | 2010-10-01 | 2012-04-05 | Ventirx Pharmaceuticals, Inc. | Méthodes de traitement de maladies allergiques |
ES2616449T3 (es) | 2010-10-01 | 2017-06-13 | Ventirx Pharmaceuticals, Inc. | Uso terapéutico de un agonista de TLR y terapia de combinación |
AU2011326427B2 (en) * | 2010-11-10 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
ES2620606T3 (es) | 2011-01-12 | 2017-06-29 | Ventirx Pharmaceuticals, Inc. | Benzoazepinas sustituidas como moduladores de receptores tipo Toll |
ES2691745T3 (es) | 2011-04-08 | 2018-11-28 | Janssen Sciences Ireland Uc | Derivados de pirimidina para el tratamiento de infecciones víricas |
EP2699271A4 (fr) | 2011-04-20 | 2015-10-07 | Larry J Smith | Procédés et compositions de modulation de l'expression des gènes à l'aide de composants qui sont auto-assemblés dans des cellules et qui produisent une activité d'arni |
EP3181555B1 (fr) | 2011-04-21 | 2018-11-28 | Gilead Sciences, Inc. | Composés de benzothiazole et leur utilisation pharmaceutique |
PT2709989T (pt) * | 2011-05-18 | 2018-03-27 | Janssen Sciences Ireland Uc | Derivados de quinazolina para o tratamento de infeções virais e outras doenças |
WO2013012915A1 (fr) * | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Composés hétérocycliques et leurs utilisations |
DK2812331T3 (en) | 2012-02-08 | 2019-04-08 | Janssen Sciences Ireland Unlimited Co | PIPERIDINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS |
ES2668422T3 (es) | 2012-04-20 | 2018-05-18 | Gilead Sciences, Inc. | Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH |
WO2013163427A1 (fr) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Anticorps pour traiter les infections par le vih-1 |
AU2013301450B2 (en) | 2012-08-10 | 2018-01-18 | Janssen Sciences Ireland Uc | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases |
SG11201502622VA (en) | 2012-10-10 | 2015-05-28 | Janssen Sciences Ireland Uc | PYRROLO[3,2-<i>D</i>]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES |
EP2925729B1 (fr) | 2012-11-16 | 2017-10-18 | Janssen Sciences Ireland UC | Dérivés de 2-amino-quinazoline substitué hétérocycliques pour le traitement d'infections virales |
US9598378B2 (en) | 2013-02-21 | 2017-03-21 | Janssen Sciences Ireland Uc | 2-aminopyrimidine derivatives for the treatment of viral infections |
NO2865735T3 (fr) | 2013-07-12 | 2018-07-21 | ||
PT3019503T (pt) | 2013-07-12 | 2017-11-27 | Gilead Sciences Inc | Compostos carbamoílpiridona- policíclicos e seu uso para o tratamento de infecções por hiv |
CU20180011A7 (es) * | 2015-03-04 | 2018-06-05 | Gilead Sciences Inc | Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll |
-
2016
- 2016-09-13 US US15/759,177 patent/US20180263985A1/en not_active Abandoned
- 2016-09-13 AU AU2016322763A patent/AU2016322763A1/en not_active Abandoned
- 2016-09-13 US US15/264,401 patent/US20170071944A1/en not_active Abandoned
- 2016-09-13 JP JP2018513529A patent/JP2018527366A/ja active Pending
- 2016-09-13 CA CA2997955A patent/CA2997955A1/fr not_active Abandoned
- 2016-09-13 WO PCT/US2016/051545 patent/WO2017048727A1/fr active Application Filing
- 2016-09-13 EP EP16770854.4A patent/EP3349757A1/fr not_active Withdrawn
- 2016-09-13 MA MA042818A patent/MA42818A/fr unknown
-
2018
- 2018-12-21 HK HK18116414.4A patent/HK1257270A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
HK1257270A1 (zh) | 2019-10-18 |
EP3349757A1 (fr) | 2018-07-25 |
WO2017048727A1 (fr) | 2017-03-23 |
AU2016322763A1 (en) | 2018-04-19 |
CA2997955A1 (fr) | 2017-03-23 |
JP2018527366A (ja) | 2018-09-20 |
US20170071944A1 (en) | 2017-03-16 |
US20180263985A1 (en) | 2018-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42818A (fr) | Modulateurs de récepteurs de type toll pour le traitement du vih | |
MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
MA43382A (fr) | Modulateurs des récepteurs des chimiokines | |
MA48448A (fr) | Dérivés de quinazoline utilisés pour traiter le vih | |
MA41449A (fr) | Polythérapies pour le traitement de cancers | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
BR112017028484A2 (pt) | fundir chamadas de grupo ativas | |
MA53943A (fr) | Modulateurs de ror-gamma | |
DK3359160T3 (da) | Farnesoid x receptor modulatorer | |
MA55328A (fr) | Modulateurs de ror-gamma | |
MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
MA45429A (fr) | Polythérapie pour le traitement du cancer | |
MA46963A (fr) | Méthodes pour déterminer le dosage de céllules car-t | |
MA41555A (fr) | Polythérapie pour le traitement du cancer | |
FR3036518B1 (fr) | Inversion pour contrainte tectonique | |
FR3042807B1 (fr) | Autolestage pour banche de coffrage | |
MA42999A (fr) | Polythérapie pour le traitement de malignités | |
DK3490986T3 (da) | Piperidin-cxcr7-receptormodulatorer | |
BR112017024750A2 (pt) | dispositivo de cofragem | |
MA41123A (fr) | Polythérapie pour le traitement du cancer | |
MA44378A (fr) | Protéines de fusion immunogènes pour le traitement du cancer | |
MA40690A (fr) | Poutre pour grue | |
FR3021224B1 (fr) | Phytomedicament pour le vih | |
MA41202A (fr) | Copolymères polydiallymine réticulé pour le traitement du diabète de type 2 | |
FR3039220B1 (fr) | Dipositif de postcombustion pour turboreacteur |